Currently holds positions in Novartis AG, SAGE Therapeutics Inc and Urogen Pharma Ltd
Position | Company | Period |
---|---|---|
CEO, Novartis Oncology | Novartis AG | Feb. 1, 2018 - |
Independent Director | SAGE Therapeutics Inc | Jan. 23, 2019 - |
President, Chief Executive Officer, Director | Urogen Pharma Ltd | Jan. 3, 2019 - |
Search
Notification date | Transaction date | B/S Transaction type |
Nb. shares Price Value |
Number of shares | Price | Total value | Details | |
---|---|---|---|---|---|---|---|---|
2023-08-11 | 2023-08-09 |
SAGE Therapeutics Inc
(SAGE)
|
B Purchase |
2,000
+200.0%
18.6437,279 USD |
2,000 +200.0% | 18.64 | 37,279 USD | |
2023-05-11 | 2023-05-09 |
SAGE Therapeutics Inc
(SAGE)
|
B Purchase |
1,000
+inf%
50.5050,500 USD |
1,000 +inf% | 50.50 | 50,500 USD | |
2022-02-02 | 2022-01-31 |
Urogen Pharma Ltd
(URGN)
|
S Sale |
5,960
-1.9%
7.5845,177 USD |
5,960 -1.9% | 7.58 | 45,177 USD | |
2022-02-02 | 2022-01-31 |
Urogen Pharma Ltd
(URGN)
|
S Sale |
2,235
-0.7%
7.5816,941 USD |
2,235 -0.7% | 7.58 | 16,941 USD | |
2022-01-07 | 2022-01-04 |
Urogen Pharma Ltd
(URGN)
|
S Sale |
46,968
-13.6%
9.15429,757 USD |
46,968 -13.6% | 9.15 | 429,757 USD | |
2020-12-15 | 2020-12-14 |
Urogen Pharma Ltd
(URGN)
|
B Purchase |
10,000
+4.6%
18.50185,000 USD |
10,000 +4.6% | 18.50 | 185,000 USD |